Search Result

Results for "

sphingosine 1-phosphate receptors

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Drug Isomer (1) Fluorescent Dye (1) Isotope-Labeled Compounds (1) LPL Receptor (26) PAK (1) Phosphodiesterase (PDE) (1) Reference Standards (4)
By Research Areas:	Cancer (3) Cardiovascular Disease (2) Infection (2) Inflammation/Immunology (19) Metabolic Disease (2) Neurological Disease (13)

Inhibitors & Agonists

Isotope-Labeled Compounds

Targets Recommended: SphK

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-12288

Ozanimod 4 Publications Verification RPC-1063	LPL Receptor	Neurological Disease Inflammation/Immunology
Ozanimod (RPC-1063) is a CNS-penetrant sphingosine 1-phosphate (S1P) receptor modulator that binds with high affinity selectively to S1P receptor subtypes 1 (S1P1) and 5 (S1P5). Ozanimod has modulate effect for hS1P₁ and hS1P₅ receptor with EC₅₀s of 1.03 nM and 8.6 nM, respectively. Ozanimod can be used for the research of relapsing multiple sclerosis (MS) .

HY-12288A

Ozanimod hydrochloride 4 Publications Verification RPC-1063 hydrochloride	LPL Receptor	Neurological Disease Inflammation/Immunology
Ozanimod (RPC-1063) hydrochloride, a sphingosine 1-phosphate (S1P) receptor modulator that binds with high affinity selectively to S1P receptor subtypes 1 (S1P1) and 5 (S1P5). Ozanimod hydrochloride has modulate effect for hS1P₁ and hS1P₅ receptor with EC₅₀s of 1.03 nM and 8.6 nM, respectively. Ozanimod hydrochloride can be used for the research of relapsing multiple sclerosis (MS) .

HY-15381

Fingolimod phosphate 1 Publications Verification FTY720 phosphate	LPL Receptor	Infection Neurological Disease Inflammation/Immunology
Fingolimod phosphate (FTY720 phosphate) is an orally active **sphingosine 1-phosphate (S1P) receptor** agonist. Fingolimod phosphate can promote the neuroprotective effects of microglia. Fingolimod phosphate can be used for the research of multiple sclerosis and neurologic diseases .

HY-16734A

Amiselimod hydrochloride MT-1303 hydrochloride	LPL Receptor	Cardiovascular Disease Inflammation/Immunology
Amiselimod (MT-1303) hydrochloride is converted to its active metabolite Amiselimod phosphate by sphingosine kinases in vivo. Amiselimod hydrochloride is an orally active and high selectivity sphingosine 1-phosphate receptor-1 (S1P1) agonist, designed to reduce the bradycardia effects associated with fingolimod and other S1P receptor modulators. Amiselimod hydrochloride inhibits chronic colitis via inhibiting infiltration of colitogenic Th1 and Th17 cells into the colon. Amiselimod hydrochloride inhibits lupus nephritis by reducing the infiltration of autoreactive T cells into the kidneys. Amiselimod hydrochloride is promising for research of autoimmune diseases .

HY-10968

CYM5442 3 Publications Verification	LPL Receptor	Neurological Disease
CYM5442 is a potent, highly-selective and orally active **sphingosine 1-phosphate (S1P1) receptor agonist with an EC₅₀ of 1.35 nM. CYM5442 is inactive against S1P2, S1P3, S1P4, and S1P5. CYM5442 activates S1P1**-dependent p42/p44-MAPK phosphorylation. CYM5442 exerts retinal neuroprotection. CYM5442 can easily penetrate the central nervous system (CNS) .

HY-117213

Ex26 S1P1-IN-Ex26	LPL Receptor	Neurological Disease Metabolic Disease Inflammation/Immunology
Ex26 (S1P1-IN-Ex26) is a potent and selective sphingosine 1-phosphate receptor 1 (S1P₁) antagonist (IC₅₀=0.93 nM). Ex26 shows >3,000-fold selectivity for S1P₁ over other Sphingosine 1-phosphate receptors. Ex26 can be used in experimental autoimmune encephalomyelitis reseach .

HY-12685

Ceralifimod ONO-4641	LPL Receptor	Neurological Disease
Ceralifimod (ONO-4641) is selective, high potent agonist for sphingosine 1-phosphate receptors 1 and 5, with EC₅₀s of 27.3, 334 pM for human S1P receptor 1 and 5, respectively.

HY-108490

VPC 23019	LPL Receptor	Inflammation/Immunology
VPC 23019, an aryl amide-containing Sphingosine 1-phosphate (S1P) analog, is a competitive antagonist at the S1P1 and S1P3 receptors (pK_i= 7.86 and 5.93, respectively) and an agonist at the S1P4 and S1P5 receptors (pEC₅₀= 6.58 and 7.07, respectively) .

HY-158417

KSI-6666	LPL Receptor	Inflammation/Immunology
KSI-6666 is an orally active, competitive antagonist for sphingosine 1-phosphate receptor 1 (S1PR1), with an IC₅₀ of 6.4 nM. KSI-6666 exhibits anti-inflammatory efficacy in autoimmune encephalomyelitis model and T cell transfer colitis model .

HY-158638

NBD-FTY720 phenoxy hydrochloride	Fluorescent Dye	Others
NBD-FTY720 phenoxy hydrochloride is a fluorescently-labeled analog of FTY720. FTY720 (HY-12005) is a potent sphingosine 1-phosphate (S1P) receptors modulator .

HY-111021

ASP-4058 1 Publications Verification	LPL Receptor	Inflammation/Immunology
ASP-4058 is a next-generation, selective and oral bioactive agonist for Sphingosine 1-Phosphate receptors 1 and 5 (S1P₁ and S1P₅), ameliorates rodent experimental autoimmune encephalomyelitis with a favorable safety profile .

HY-100953

CYM-5520 1 Publications Verification	LPL Receptor	Metabolic Disease
CYM-5520 is a selective and allosteric sphingosine 1-phosphate receptor 2 (S1PR2) agonist with an EC₅₀ of 480 nM. CYM-5520 does not activate S1PR1, S1PR3, S1PR4 and S1PR5 receptors. CYM-5520 can co-bind in the S1PR2 receptor with S1P. CYM-5520 can be used for osteoporosis research .

HY-12288R

Ozanimod (Standard) RPC-1063 (Standard)	Reference Standards LPL Receptor	Neurological Disease Inflammation/Immunology
Ozanimod (Standard) is the analytical standard of Ozanimod. This product is intended for research and analytical applications. Ozanimod (RPC-1063), a sphingosine 1-phosphate (S1P) receptor modulator that binds with high affinity selectively to S1P receptor subtypes 1 (S1P1) and 5 (S1P5). Ozanimod has modulate effect for hS1P₁ and hS1P₅ receptor with EC₅₀s of 1.03 nM and 8.6 nM, respectively. Ozanimod can be used for the research of relapsing multiple sclerosis (MS) .

HY-14976

CS-0777	LPL Receptor	Inflammation/Immunology
CS-0777 is a selective, orally active **sphingosine 1-phosphate** receptor-1 modulator. CS-0777 can be used in the research of autoimmune diseases .

HY-12005R

Fingolimod hydrochloride (Standard) FTY720 (Standard)	Reference Standards LPL Receptor PAK	Inflammation/Immunology Cancer
Fingolimod (hydrochloride) (Standard) is the analytical standard of Fingolimod (hydrochloride). This product is intended for research and analytical applications. Fingolimod hydrochloride (FTY720), an analog of sphingosine, is a potent **sphingosine 1-phosphate (S1P*) receptors* modulator. Fingolimod hydrochloride is phosphorylated by sphingosine kinases, particularly by SK2, and then binds S1PR1, 3, 4, and 5. Fingolimod hydrochloride induces the internalization of S1P1, and consequently, inhibits S1P activity. Fingolimod hydrochloride also is a pak1 activator .

HY-16734

Amiselimod MT-1303	LPL Receptor	Cardiovascular Disease Inflammation/Immunology
Amiselimod (MT-1303) is converted to its active metabolite Amiselimod phosphate by sphingosine kinases in vivo. Amiselimod is an orally active and high selectivity sphingosine 1-phosphate receptor-1 (S1P1) agonist, designed to reduce the bradycardia effects associated with fingolimod and other S1P receptor modulators. Amiselimod inhibits chronic colitis via inhibiting infiltration of colitogenic Th1 and Th17 cells into the colon. Amiselimod inhibits lupus nephritis by reducing the infiltration of autoreactive T cells into the kidneys. Amiselimodis promising for research of autoimmune diseases .

HY-10968A

CYM5442 hydrochloride	LPL Receptor	Neurological Disease
CYM5442 hydrochloride is a potent, highly-selective and orally active **sphingosine 1-phosphate (S1P1) receptor agonist with an EC₅₀ of 1.35 nM. CYM5442 hydrochloride is inactive against S1P2, S1P3, S1P4, and S1P5. CYM5442 hydrochloride activates S1P1**-dependent p42/p44-MAPK phosphorylation. CYM5442 exerts retinal neuroprotection. CYM5442 hydrochloride can easily penetrate the central nervous system (CNS) .

HY-116088

W123	LPL Receptor	Inflammation/Immunology
W123, a FTY720 analog, is a competitive **sphingosine 1-phosphate type 1 (S1P1) receptor** antagonist. W123 is measured by GTPγS activation, MAPK recruitment, cell migration, and ligand-induced receptor internalization .

HY-111292

CYM-5482	LPL Receptor	Cancer
CYM-5482 is a potent and selective agonist Sphingosine 1-phosphate receptor 2 (S1PR2) with an IC₅₀ and EC₅₀ of 1.0 and 1.03 μM. CYM-5482 has the potential for the research of cancer diseases .

HY-111021A

ASP-4058 hydrochloride 1 Publications Verification	LPL Receptor	Inflammation/Immunology
ASP-4058 hydrochloride is a next-generation, selective and orally active agonist for Sphingosine 1-Phosphate receptors 1 and 5 (S1P₁ and S1P₅), ameliorates rodent experimental autoimmune encephalomyelitis with a favorable safety profile .

HY-15381R

Fingolimod phosphate (Standard) FTY720 phosphate (Standard)	LPL Receptor Reference Standards	Infection Neurological Disease Inflammation/Immunology
Fingolimod phosphate (Standard) is the analytical standard of Fingolimod phosphate. This product is intended for research and analytical applications. Fingolimod phosphate (FTY720 phosphate) is an orally active sphingosine 1-phosphate (S1P) receptor agonist. Fingolimod phosphate can promote the neuroprotective effects of microglia. Fingolimod phosphate can be used for the research of multiple sclerosis and neurologic diseases .

HY-137973

RP-1859	LPL Receptor	Inflammation/Immunology
RP-1859 is a **sphingosine 1-phosphate receptor (S1P**) modulator. RP-1859 exerts anti-inflammatory and immunomodulatory activities. RP-1859 can be used for the research of iatrogenic autoimmune colitis .

HY-10968R

CYM5442 (Standard)	LPL Receptor	Neurological Disease
CYM5442 (Standard) is the analytical standard of CYM5442. This product is intended for research and analytical applications. CYM5442 is a potent, highly-selective and orally active sphingosine 1-phosphate (S1P1) receptor agonist with an EC50 of 1.35 nM. CYM5442 is inactive against S1P2, S1P3, S1P4, and S1P5. CYM5442 activates S1P1-dependent p42/p44-MAPK phosphorylation. CYM5442 exerts retinal neuroprotection. CYM5442 can easily penetrate the central nervous system (CNS) .

HY-W751034A

(R)-Ozanimod hydrochloride (R)-RPC-1063 hydrochloride	Drug Isomer	Neurological Disease Inflammation/Immunology
(R)-Ozanimod (hydrochloride) is the R-isomer of Ozanimod hydrochloride (HY-12288A) .

HY-182618

XAX-162	LPL Receptor	Others
XAX-162 is a highly selective sphingosine 1-phosphate receptor 2 (S1PR2) agonist with a human EC₅₀ of 0.55 μM. XAX-162 does not activate other S1P receptors. XAX-162 exhibits noncompetitive inhibition of activity by S1PR2 antagonist JTE-013 (HY-100675) .

HY-164584

S1P5 receptor antagonist 1	LPL Receptor	Neurological Disease
S1P5 receptor antagonist 1 is a selective, blood-brain barrier-permeable S1P5 receptor antagonist with an EC₅₀ of 0.1 nM and a K_i of 4.4 nM. S1P5 receptor antagonist 1 inhibits the migration of natural killer cells towards sphingosine 1-phosphate in vitro, with no effect on T cell migration. S1P5 receptor antagonist 1 can be used in the research of central nervous system diseases .

HY-108490R

VPC 23019 (Standard)	Reference Standards LPL Receptor	Inflammation/Immunology
VPC 23019 (Standard) is the analytical standard of VPC 23019 (HY-108490). This product is intended for research and analytical applications. VPC 23019, an aryl amide-containing Sphingosine 1-phosphate (S1P) analog, is a competitive antagonist at the S1P1 and S1P3 receptors (pK_i= 7.86 and 5.93, respectively) and an agonist at the S1P4 and S1P5 receptors (pEC₅₀= 6.58 and 7.07, respectively) .

HY-12288S

Ozanimod-d6 RPC-1063-d₆	Isotope-Labeled Compounds LPL Receptor	Neurological Disease Inflammation/Immunology
Ozanimod-d₆ (RPC-1063-d₆) is the deuterium labeled Ozanimod (HY-12288). Ozanimod (RPC-1063) is a CNS-penetrant sphingosine 1-phosphate (S1P) receptor modulator that binds with high affinity selectively to S1P receptor subtypes 1 (S1P1) and 5 (S1P5). Ozanimod has modulate effect for hS1P₁ and hS1P₅ receptor with EC₅₀s of 1.03 nM and 8.6 nM, respectively. Ozanimod can be used for the research of relapsing multiple sclerosis (MS) .

HY-119601

GRI918013	Phosphodiesterase (PDE)	Cancer
GRI918013 (compound 1) is a selective and competitive autotaxin (ATX/NPP2) inhibitor with anti-invasive and anti-metastatic activity. GRI918013 competitively binds to ATX, blocking lipid substrates such as lysophosphatidylcholine (LPC) from entering the ATX active site, thereby inhibiting ATX-mediated hydrolysis of LPC to lysophosphatidic acid (LPA), and consequently inhibiting ATX-LPA axis-related tumor cell invasion and metastasis. GRI918013 inhibits ATX-mediated hydrolysis of the LPL substrate FS-3 (IC₅₀=31.42 nM, K_i=12.98 nM). GRI918013 can be used in research on cancer invasion and metastasis, such as melanoma, and can also serve as a tool compound for ATX-LPA axis-related diseases such as fibrotic diseases, neuropathic pain, and cholestatic pruritus .

Cat. No.	Product Name	Chemical Structure

HY-12288S

Ozanimod-d6
Ozanimod-d₆ (RPC-1063-d₆) is the deuterium labeled Ozanimod (HY-12288). Ozanimod (RPC-1063) is a CNS-penetrant sphingosine 1-phosphate (S1P) receptor modulator that binds with high affinity selectively to S1P receptor subtypes 1 (S1P1) and 5 (S1P5). Ozanimod has modulate effect for hS1P₁ and hS1P₅ receptor with EC₅₀s of 1.03 nM and 8.6 nM, respectively. Ozanimod can be used for the research of relapsing multiple sclerosis (MS) .

Ozanimod-d6

Ozanimod-d₆ (RPC-1063-d₆) is the deuterium labeled Ozanimod (HY-12288). Ozanimod (RPC-1063) is a CNS-penetrant sphingosine 1-phosphate (S1P) receptor modulator that binds with high affinity selectively to S1P receptor subtypes 1 (S1P1) and 5 (S1P5). Ozanimod has modulate effect for hS1P₁ and hS1P₅ receptor with EC₅₀s of 1.03 nM and 8.6 nM, respectively. Ozanimod can be used for the research of relapsing multiple sclerosis (MS) .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.